RecruitingPhase 2NCT07037901

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Sponsor

Inmagene LLC

Enrollment

405 participants

Start Date

Jun 17, 2025

Study Type

INTERVENTIONAL

Conditions

atopic dermatitis (eczema)Atopic Dermatitis Eczema

Summary

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Eligibility

Min Age: 18 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IMG-007 and a drug called Placebo for people with atopic dermatitis, eczema, and other related conditions. The study is currently recruiting participants at 23 locations. People eligible for this study include aged 18 Years to 74 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIMG-007

Participants will receive IMG-007 subcutaneously.

DRUGPlacebo

Participants will receive a placebo subcutaneously.

Locations(23)

Inmagene Site 1

Lancaster, California, United States

Inmagene Site 23

Los Angeles, California, United States

Inmagene Site 19

Ocala, Florida, United States

Inmagene Site 4

Tampa, Florida, United States

Inmagene Site 2

Rolling Meadows, Illinois, United States

Inmagene Site 6

Kew Gardens, New York, United States

Inmagene Site 21

New York, New York, United States

Inmagene Site 11

Woodbury, New York, United States

Inmagene Site 20

Charlotte, North Carolina, United States

Inmagene Site 10

Fargo, North Dakota, United States

Inmagene Site 9

Columbus, Ohio, United States

Inmagene Site 5

Mayfield Heights, Ohio, United States

Inmagene Site 3

Portland, Oregon, United States

Inmagene Site 12

Anderson, South Carolina, United States

Inmagene Site 8

Southlake, Texas, United States

Inmagene Site 7

Burien, Washington, United States

Inmagene Site 15

Surrey, British Columbia, Canada

Inmagene Site 22

Vancouver, British Columbia, Canada

Inmagene Site 17

Greater Sudbury, Ontario, Canada

Inmagene Site 13

Mississauga, Ontario, Canada

Inmagene Site 18

North Bay, Ontario, Canada

Inmagene Site 14

Montreal, Quebec, Canada

Inmagene Site 16

Saskatoon, Saskatchewan, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07037901

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Effects of Treatments on Atopic Dermatitis

NCT016316171 location

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT0639791116 locations

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT006058781 location

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

NCT065994111 location